Details

Autor(en) / Beteiligte

• Shimano, Kristin A.
• Neunert, Cindy
• Bussel, James B.
• Klaassen, Robert J.
• Bhat, Rukhmi
• Pastore, Yves D.
• Lambert, Michele P.
• Bennett, Carolyn M.
• Despotovic, Jenny M.
• Forbes, Peter
• Grace, Rachael F.

Titel

Quality of life is an important indication for second‐line treatment in children with immune thrombocytopenia

Ist Teil von

• Pediatric blood & cancer, 2021-06, Vol.68 (6), p.e29023-n/a

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2021

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Background The decision to initiate second‐line treatment in children with immune thrombocytopenia (ITP) is complex and involves many different factors. Methods In this prospective, observational, longitudinal cohort study of 120 children from 21 centers, the factors contributing to the decision to start second‐line treatments for ITP were captured. At study entry, clinicians were given a curated list of 12 potential reasons the patient required a second‐line treatment. Clinicians selected all that applied and ranked the top three reasons. Results Quality of life (QOL) was the most frequently cited reason for starting a second‐line therapy. Clinicians chose it as a reason to treat in 88/120 (73%) patients, as among the top three reasons in 68/120 (57%), and as the top reason in 32/120 (27%). Additional factors ranked as the top reason to start second‐line treatment included severity of bleeding (22/120, 18%), frequency of bleeding (19/120, 16%), and severity of thrombocytopenia (18/120, 15%). Patients for whom QOL (p = .006) or sports participation (p = .02) were ranked reasons were more likely to have chronic ITP, whereas those for whom severity (p = .003) or frequency (p = .005) of bleeding were ranked reasons were more likely to have newly diagnosed or persistent ITP. Parental anxiety, though rarely the primary impetus for treatment, was frequently cited (70/120, 58%) as a contributing factor. Conclusion Perceived QOL is the most frequently selected reason pediatric patients start second‐line therapies for ITP. It is critical that studies of treatments for childhood ITP include assessments of their effects on QOL.